Tepmetko is a cancer medicine that is used to treat adults with non-small cell lung cancer (NSCLC) when the cancer is advanced and its cells have particular genetic mutations (changes) leading to ‘mesenchymal-epithelial transition factor gene exon 14’ (METex14) skipping. This means that the cancer cells make an abnormal form of a protein called MET because a part of the MET gene known as exon 14 is not used. Tepmetko is used when the patient needs further treatment after receiving immunotherapy or platinum-based chemotherapy, or both. Tepmetko contains the active substance tepotinib.
Therapeutic Indication
### Therapeutic indication Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Therapeutic Area (MeSH)
ATC Code
L01EX21
ATC Item
tepotinib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Tepmetko
Medicine Name
Tepmetko
Aliases
N/A
